Dolutegravir
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Dolutegravir Product Information
Dolutegravir is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Dolutegravir. The product is supplied by Clearsynth under CAT No. CS-O-00218.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Dolutegravir
CAS No.
1051375-16-6
CAT No.
CS-O-00218
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C20H19F2N3O5
Molecular Weight
419.38
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Dolutegravir is supplied with detailed characterization data compliant with regulatory guideline. Dolutegravir can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Dolutegravir.
Overview
Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peri
Synonyms
Dolutegravir
Application Notes
Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peri
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.